Insulin, glucose, and meal timing

What researchers mean by these words

Glucose is sugar in the blood. Papers usually report a fasting value (after an overnight gap), sometimes a curve after a test meal or glucose drink, and sometimes HbA1c — a slower average over about two to three months.

Insulin is a pancreatic hormone. After a meal it helps move glucose into tissues, stores glycogen, and quiets fat release and ketone production. It rises after eating, especially after carbohydrate-containing meals, and falls as the fast continues. That fall is part of the same fuel shift described in Part 4, told from the hormone side.

Insulin resistance in this literature is often an inferred story from fasting glucose and insulin (commonly HOMA-IR). It is a useful paper metric. It is not a diagnosis you get from a timer, and it is not the same sentence as “type 2 diabetes.”

Meal timing here usually means *where the eating window sits in the day* — early TRE versus late TRE — not a ranking of 16:8 versus 18:6. Two 16-hour fasts can be different interventions if one ends dinner at 3 p.m. and the other ends it at 9 p.m.

After a meal, then during a fast

A mixed meal raises glucose and insulin. How high and for how long depends on meal size, carbohydrate, protein, what you ate earlier, sleep, and how insulin-sensitive you are. A large late dinner is a different input than a modest lunch.

Hours later, insulin falls. The liver releases stored carbohydrate, then makes more glucose and oxidizes more fat. Ketones may rise later still. None of that is a personal dashboard. It is a typical sequence from supervised physiology, not a badge.

A typical 16:8 day often looks like a longer overnight gap plus a skipped breakfast or an earlier dinner. It is not a 36-hour metabolic experiment. Daily windows and multi-day fasts still should not be averaged — see Part 3.

Clock time is not the same as hours fasted

The same fasting hours can sit in different parts of the day. An 8-hour window from 7 a.m. to 3 p.m. is not the same protocol as 1 p.m. to 9 p.m., even if both are labeled 16:8.

Many people handle a given meal more cleanly earlier in the day: the same food later often produces a larger glucose and insulin response in experimental work. Small early-TRE studies sometimes show a kinder fasting-insulin or insulin-sensitivity readout than a window that runs into the night. Part 2 already flagged that as a placement finding, not a dinner ban.

Circadian research sits next to family dinners, shift work, and culture. A prettier lab average that wrecks sleep or isolates you from the household is not an automatic win. See Sleep, stress, and your fasting window.

What was typically studied

Glucose and insulin are usually secondary outcomes in TRE and ADF trials — sitting beside weight, lipids, and blood pressure. Some papers add an oral glucose test, a short CGM stretch, or HbA1c. Few consumer-facing trials map a full 24-hour insulin curve.

Early-versus-late window trials are fewer and smaller than “any daily window versus eat whenever.” One carefully controlled early-TRE study in men with prediabetes held weight steady and still saw insulin-sensitivity and blood-pressure changes. Other trials find little extra once calories and weight are similar. The field is not unanimous.

Participants are mostly adults with overweight or obesity, for weeks to a few months. A smaller set includes prediabetes or type 2 diabetes. That is not children, pregnancy, type 1 as a default, or a decade of follow-up.

What trials tend to find

Compared with eating whenever you want, fasting glucose and insulin sometimes improve. The change is often modest and often travels with weight loss. When calories are matched, the extra effect of the clock itself is smaller and less consistent — the same pattern Part 2 described for weight.

Early TRE — finishing eating in the afternoon — looks more favorable for some insulin-sensitivity, fasting-insulin, or blood-pressure measures in a handful of small, tightly run studies. That is interesting. It is not a rule that everyone must skip dinner, and later replications are mixed.

HbA1c rarely moves a lot in short TRE trials, especially in people without diabetes. That is expected: HbA1c is a slow average. A six-week window is a short lever on a three-month number.

People with type 2 diabetes appear in a smaller set of trials. Some show modest weight or glucose-average changes. That is not a license to treat diabetes with a window, and it is not safe to copy if you use insulin or a sulfonylurea without a clinician adjusting doses.

Limits (read these as part of the result)

A lower fasting insulin is a marker change. It is not proof that a disease receded, and it is not a health score.

Weight is a confounder. Separate “ate less because the kitchen closed” from “the clock healed insulin.”

Who: the same narrow enrollment as the rest of this cluster. Findings do not transfer automatically to type 1 diabetes, pregnancy, underweight people, or complex regimens.

Measurement: one fasting blood draw is not a CGM week. HOMA-IR is an estimate. Home finger-sticks you were not asked to take are not a research protocol.

Early TRE has a social cost. Evening hunger, skipped family meals, and worse sleep show up in real life even when a paper’s mean insulin looks tidier.

Safety: people on insulin or some oral glucose-lowering drugs can see glucose fall too far when they stop eating. A meal-timing story does not make that safer. See Who should be careful and When to stop a fast.

What this does not mean

It does not mean fasting reverses diabetes, “resets” the pancreas, or replaces prescribed medication. It does not mean lower insulin is always better — you need insulin. It does not mean you should chase a gadget reading.

It does not mean you must skip dinner, or that a late window is a moral failure. It does not mean 18:6 is a higher insulin dose than 16:8, or that longer hours are a treatment.

It does not mean the timer measures glucose or insulin. Stage badges remain teaching bookmarks on elapsed time — the same rule as Parts 4 and 5.

How this meets the timer

Use the clock for elapsed time and for a window you already chose. Whether that window sits earlier or later is a practice decision: sleep, household, hunger, and (if relevant) a clinician. Fundamentals still apply — start near your current overnight gap; do not jump to OMAD to chase a lab story.

If glucose is a medical topic for you, it belongs with a clinician and any meter they asked you to use — not with a stage badge. MyFastingClock will not pretend a countdown is a continuous glucose monitor.

Soft next reading in this cluster: weight, body composition, and adherence (Part 7) when that note ships. For this week, Choosing a starting window, Sleep and stress, and the safety notes still decide more than a headline about insulin.